{"id":"lupron-trigger","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":{"chemblId":"CHEMBL1200775","moleculeType":"Protein","molecularWeight":"1269.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lupron (leuprolide) is a gonadotropin-releasing hormone (GnRH) agonist that, when given as a bolus injection, induces a rapid surge in LH secretion. This LH surge mimics the natural ovulatory trigger and causes the final maturation of oocytes and rupture of the ovarian follicle, allowing egg retrieval in fertility treatment protocols. It is used as an alternative to human chorionic gonadotropin (hCG) in controlled ovarian hyperstimulation cycles.","oneSentence":"Lupron Trigger is a GnRH agonist that causes a surge in luteinizing hormone (LH) to trigger final oocyte maturation and ovulation in assisted reproductive technology cycles.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:11.843Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovulation trigger in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles"}]},"trialDetails":[{"nctId":"NCT06199986","phase":"NA","title":"DeADT - Living Well With Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06026553","phase":"PHASE1","title":"Assessing Ketorolac (Toradol) at Oocyte Retrieval","status":"UNKNOWN","sponsor":"Shady Grove Fertility Reproductive Science Center","startDate":"2022-08-10","conditions":"Infertility, Infertility, Female, Oocyte Retrieval","enrollment":400},{"nctId":"NCT04522479","phase":"NA","title":"Prolonged Protocol of Early Follicular or Mid Luteal Phase","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-05-13","conditions":"IVF","enrollment":1150},{"nctId":"NCT01443546","phase":"PHASE4","title":"Study of Dual Trigger Ovulation in Oocyte Donors","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-01","conditions":"Infertility","enrollment":26},{"nctId":"NCT01606709","phase":"PHASE4","title":"Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation","status":"TERMINATED","sponsor":"UConn Health","startDate":"2012-04","conditions":"Endometrial Receptivity, Ovarian Hyperstimulation Syndrome","enrollment":7},{"nctId":"NCT01866618","phase":"","title":"Natural Cycle In Vitro Fertilization","status":"COMPLETED","sponsor":"Reproductive Medicine Associates of New Jersey","startDate":"2013-04","conditions":"Natural Cycle in Vitro Fertilization (IVF)","enrollment":524},{"nctId":"NCT02069808","phase":"PHASE4","title":"Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation","status":"COMPLETED","sponsor":"Michigan Reproductive Medicine","startDate":"2014-04","conditions":"Egg Donation","enrollment":38},{"nctId":"NCT00804960","phase":"PHASE4","title":"Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?","status":"WITHDRAWN","sponsor":"Center for Human Reproduction","startDate":"2008-09","conditions":"Infertility","enrollment":""},{"nctId":"NCT02342106","phase":"","title":"Assessment of Myeloid Cell Constitution in the Follicular Fluid of Women Undergoing In-vitro Fertilization","status":"UNKNOWN","sponsor":"Hillel Yaffe Medical Center","startDate":"2015-01","conditions":"Infertility","enrollment":100},{"nctId":"NCT01595334","phase":"NA","title":"Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity","status":"UNKNOWN","sponsor":"Southern Cross Fertility Centre","startDate":"2012-04","conditions":"Infertility","enrollment":300},{"nctId":"NCT00349258","phase":"PHASE4","title":"The Use of GnRH Agonist Trigger in the Prevention of OHSS","status":"COMPLETED","sponsor":"University of Connecticut","startDate":"2004-08","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lupron Trigger","genericName":"Lupron Trigger","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lupron Trigger is a GnRH agonist that causes a surge in luteinizing hormone (LH) to trigger final oocyte maturation and ovulation in assisted reproductive technology cycles. Used for Triggering final oocyte maturation and ovulation in assisted reproductive technology (ART) cycles.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}